US Stock MarketDetailed Quotes

RVNC Revance Therapeutics

Watchlist
  • 4.130
  • +0.330+8.68%
Trading Nov 26 10:49 ET
433.25MMarket Cap-2151P/E (TTM)

Revance Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Revance Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 69.300M--
--2024/Q4-- / 83.350M--
--2024/Q359.879M / 68.175M--
Aug 8, 20242024/Q265.389M / 66.290M--
May 9, 20242024/Q151.936M / 56.658M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 69.300M--
--2024/Q4-- / 83.350M--
--2024/Q359.879M / 68.175M--
Aug 8, 20242024/Q265.389M / 66.290M--
May 9, 20242024/Q151.936M / 56.658M--

Unlock Free Earnings Estimates

Revance Therapeutics Earnings Reports

  • Revance Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 7 16:26 ET

  • Revance Therapeutics | 8-K: Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update

    Nov 7 16:21 ET

  • Revance Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 8 16:40 ET

  • Revance Therapeutics | 8-K: Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update

    Aug 8 16:10 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 12, 2024

    Hold

    • Buy

      0.00%

    • Hold

      100.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data